Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.

Autor: Rizvi NA; Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA. rizvin@mskcc.org, Marshall JL, Ness E, Hawkins MJ, Kessler C, Jacobs H, Brenckman WD Jr, Lee JS, Petros W, Hong WK, Kurie JM

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2002 Aug 15; Vol. 20 (16), pp. 3522-32.

Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.

Autor: Chua CC; Duke University Medical Center, Durham, North Carolina., Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS

Publikováno v: Annals of internal medicine [Ann Intern Med] 1988 Jul 15; Vol. 109 (2), pp. 114-7.

Initial clinical studies of piritrexim.

Autor: Laszlo J; Duke Medical Center, Durham, NC., Brenckman WD Jr, Morgan E, Clendeninn NJ, Williams T, Currie V, Young C

Publikováno v: NCI monographs : a publication of the National Cancer Institute [NCI Monogr] 1987 (5), pp. 121-5.

Clinical experience with CF-FUra.

Autor: Laufman LR; Columbus CCOP, OH 43215., Brenckman WD Jr, Stydnicki KA, Morgan ED, Collier M, Knick VB, Duch DS, Mullin R, Ferone R

Publikováno v: Advances in experimental medicine and biology [Adv Exp Med Biol] 1988; Vol. 244, pp. 201-11.

Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer.

Autor: Brenckman WD Jr, Lastinger LB, Sedor F

Publikováno v: JAMA [JAMA] 1981 Jun 26; Vol. 245 (24), pp. 2501-4.